~~<i id='61E4BCDD35'><strike id='61E4BCDD35'><tt id='61E4BCDD35'><pre id='61E4BCDD35'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：comprehensive 2025-10-06 16:01:18 Page View：64245

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： NIH documents show early flaws of $1.6 billion long Covid program
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

comprehensive

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

How medical schools plan to diversify without affirmative action

Fromlefttoright,toprow:STAT'sUshaLeeMcFarling;Vanderbilt'sConsueloWilkins;CarolinaReyesofUCDavisHeal

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

FDA proposes changes to key medical devices approval pathway

Lastweek,theFDAreleasedatrioofguidelinesclarifyingthewaytheyplantoevaluatedevicesthatgothroughthe510